Ontology highlight
ABSTRACT:
SUBMITTER: Bond DA
PROVIDER: S-EPMC7688551 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Bond David A DA Huang Ying Y Fisher James L JL Ruppert Amy S AS Owen Dwight H DH Bertino Erin M EM Rogers Kerry A KA Bhat Seema A SA Grever Michael R MR Jaglowski Samantha M SM Maddocks Kami J KJ Byrd John C JC Woyach Jennifer A JA
Leukemia 20200723 12
Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resulting in partial restoration of immune function. The incidence of and risk factors for SPM in CLL patients receiving BTKi are not yet characterized. We retrospectively determined the incidence of SPM in CLL patients treated with ibrutinib or acalabrutinib at our institution between 2009 and ...[more]